The case continues toward trial on most claims, increasing Sandoz's litigation risk and potential settlement pressure. Monitor for trial scheduling, settlement discussions, or additional summary judgment motions. The dismissal of the Fluocinonide-with-Sandoz claim is a minor positive but does not offset the broader risk.
Price Chart
Executive Summary
The District of Connecticut denied in part Actavis's motion for summary judgment in the multi-state generic drug price-fixing antitrust case, allowing most conspiracy claims to proceed to trial. For Sandoz, the ruling is mixed: the court dismissed the claim that Sandoz conspired with Actavis on Fluocinonide solution, but all other claims against Sandoz (involving Ciclopirox, Desonide, Metronidazole, Nystatin, Terconazole, and Fluocinonide with Taro) survive. Sandoz remains a defendant in a massive litigation with 50 state plaintiffs and potential treble damages.
Court Ruling Details
Key Facts
- Court denied summary judgment for Actavis on most drugs, meaning conspiracy claims against Sandoz on those drugs survive.
- Court granted summary judgment for Actavis on Fluocinonide solution with Sandoz, dismissing that specific conspiracy claim.
- Sandoz remains a defendant in a multi-state antitrust case alleging price-fixing, market allocation, and bid-rigging on dozens of generic drugs.
- The ruling allows the case to proceed to trial on the majority of the alleged conspiracies involving Sandoz.
Financial Impact
Potential treble damages on sales of multiple generic drugs over several years; no specific amount stated in the ruling.
Risk Factors
- Adverse jury verdict could result in substantial treble damages and injunctive relief.
- Ongoing litigation costs and management distraction.
- Potential reputational harm from findings of collusion.
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-82ad0136ee-SDZ |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | Court Ruling | — | awaiting T+20 | — | — |
Oct 7, 2026 20d ago | Court Ruling | — | awaiting T+20 | — | — |
Sep 30, 2026 27d ago | Court Ruling | — | awaiting T+20 | — | — |
Sep 30, 2026 27d ago | Court Ruling | — | awaiting T+20 | — | — |
Sep 11, 2026 6w ago | Court Ruling | — | awaiting T+20 | — | — |
Aug 12, 2026 10w ago | Court Ruling | — | awaiting T+20 | — | — |
Aug 6, 2026 11w ago | Court Ruling | — | awaiting T+20 | — | — |
Jul 22, 2026 13w ago | Court Ruling | — | awaiting T+20 | — | — |
Jul 8, 2026 15w ago | Court Ruling | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers